Kansas City VA Hospital
Kansas City, Missouri, 64128, United States
Location status: Recruiting
NCT Number: NCT05570448
This will be a randomized clinical trial examining the efficacy and safety of ARAT (intervention group) in patients with chronic GERD symptoms (typical symptoms of GERD, i.e. heartburn or acid reflux/regurgitation at least twice a week) for the last 6 months.
Patients must have a positive pH test and a negative manometry (no treatment) procedure.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Kansas City, Missouri, 64128, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
For patients randomized to ARAT intervention, the area of cardia, along greater curvature will be cleaned followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC (30W, Effect 2) using the H-APC catheter. Next, the area of cardia, on either side will be injected in sequence using a methylene blue (0.5%) and normal saline (0.9%) using the H-APC catheter jet system (Effect 30-70). Next, the mucosa, starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W till golden-brown discoloration of the ablated tissue in 270-320 degree. For patients randomized to control or sham intervention, upper endoscopy with procedural sedation was performed followed by markings of landmarks followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time. No H-APC or submucosal injection or other intervention will be performed.
Other names: Anti-reflux mucosal ablation
Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
Time frame: At 3, 6 and 12 months
The primary outcome of quality of life will be measured using the validated GERD related quality of life questionnaire (GERD-HRQL). The total score is 50, and a higher score is associated with more severe symptoms.
Time frame: At 3, 6 and 12 months
RDQ scores will be assessed using a validated questionnaire scale. The total score is 40, and a higher score is associated with more severe symptoms.
Time frame: At 3, 6 and 12 months
Frequency of PPI medication use
Time frame: At 3 and 12 months
Ambulatory acid reflux testing (wireless pH monitoring system) for measurement. Acid exposure time measures amount of time spent in pH <4. A time >4% is considered positive for acid reflux.
Time frame: Post-randomization (Day 1, Day 30, 3rd, 6th and 12th month)
Frequency of any adverse event including chest pain, bleeding, dysphagia, hospitalization
Time frame: At 3 and 12 months
Hill grade for hiatal hernia assessment during endoscopy. There are 4 grades: I, II, III and IV depending on the appearance of the hiatus on endoscopy.
Time frame: At 3 and 12 months
LA grade esophagitis at the time of endoscopy
Interested in participating?
Request InfoMidwest Veterans' Biomedical Research Foundation
Other
Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: A Single Center, Randomized, Sham, Controlled Trial (The AREA Study)
Acronym: AREA21
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07795645
Arterial Occlusive Diseases, Arteriosclerosis
Beijing, China
View Trial DetailsNCT05455359
Aspiration Pneumonia, Deglutition Disorders
Boston, Massachusetts, United States
View Trial DetailsNCT05180253
Deglutition Disorders, Digestive System Diseases
Louisville, Kentucky, United States
View Trial DetailsNCT04494048
Bariatric Surgery Candidate, Body Weight
New York, United States
View Trial Details